Literature DB >> 29916557

Guidelines for the investigation and management of Transient Leukaemia of Down Syndrome.

Oliver Tunstall1, Neha Bhatnagar2, Beki James3, Alice Norton4, Aengus S O'Marcaigh5, Tim Watts6, Anne Greenough7, Paresh Vyas2,8, Irene Roberts2,8,9, Michael Wright9,10.   

Abstract

Entities:  

Keywords:  down syndrome; neonatal leukaemia; transient abnormal myelopoiesis; transient leukaemia; transient myeloproliferative disorder

Mesh：

Substances：

Year:  2018        PMID： 29916557     DOI： 10.1111/bjh.15390

Source DB:  PubMed          Journal:  Br J Haematol        ISSN： 0007-1048            Impact factor:   6.998


× No keyword cloud information.
  6 in total

1.  Two Novel GATA1 Mutations in Transient Abnormal Myelopoiesis of Thai Neonates with Down Syndrome.

Authors:  Kanokporn Chukua; Chayanont Netsawang; Kittipoom Padungthai; Thanitchet Khetkham; Piyaporn Chokevittaya; Onapinya Poonjearansilp; Sariya Prachuktum; Sudatip Kositamongkol; Wiliporn Techasatit; Phakatip Silapamongkolkul; Wallee Satayasai; Tasama Pusongchai; Pacharapan Surapolchai; Kitiwan Rojnueangnit
Journal:  J Pediatr Genet       Date:  2019-09-11

Review 2.  Clinical and biological aspects of myeloid leukemia in Down syndrome.

Authors:  Austin C Boucher; Kenneth J Caldwell; John D Crispino; Jamie E Flerlage
Journal:  Leukemia       Date:  2021-09-13       Impact factor: 12.883

3.  Clonal Myeloproliferative Disorders in Patients with Down Syndrome-Treatment and Outcome Results from an Institution in Argentina.

Authors:  Carla L Pennella; Tamara Muñoz Cassina; Jorge G Rossi; Edgardo M Baialardo; Patricia Rubio; María A Deu; Luisina Peruzzo; Myriam R Guitter; Cristian G Sanchez de La Rosa; Elizabeth M Alfaro; María S Felice
Journal:  Cancers (Basel)       Date:  2022-07-05       Impact factor: 6.575

Review 4.  Down syndrome.

Authors:  Stylianos E Antonarakis; Brian G Skotko; Michael S Rafii; Andre Strydom; Sarah E Pape; Diana W Bianchi; Stephanie L Sherman; Roger H Reeves
Journal:  Nat Rev Dis Primers       Date:  2020-02-06       Impact factor: 52.329

5.  Predictive factors for the development of leukemia in patients with transient abnormal myelopoiesis and Down syndrome.

Authors:  Genki Yamato; Takao Deguchi; Kiminori Terui; Tsutomu Toki; Tomoyuki Watanabe; Takahiro Imaizumi; Asahito Hama; Shotaro Iwamoto; Daisuke Hasegawa; Takahiro Ueda; Tomoko Yokosuka; Shiro Tanaka; Ryu Yanagisawa; Katsuyoshi Koh; Akiko M Saito; Keizo Horibe; Yasuhide Hayashi; Souichi Adachi; Shuki Mizutani; Takashi Taga; Etsuro Ito; Kenichiro Watanabe; Hideki Muramatsu
Journal:  Leukemia       Date:  2021-03-03       Impact factor: 11.528

6.  Guideline for management of non-Down syndrome neonates with a myeloproliferative disease on behalf of the I-BFM AML Study Group and EWOG-MDS.

Authors:  Eline J M Bertrums; C Michel Zwaan; Daisuke Hasegawa; Valerie De Haas; Dirk N Reinhardt; Franco Locatelli; Barbara De Moerloose; Michael Dworzak; Arjan Buijs; Petr Smisek; Alexandra Kolenova; Cornelis Jan Pronk; Jan-Henning Klusmann; Ana Carboné; Alina Ferster; Evangelia Antoniou; Soheil Meshinchi; Susana C Raimondi; Charlotte M Niemeyer; Henrik Hasle; Marry M Van den Heuvel-Eibrink; Bianca F Goemans
Journal:  Haematologica       Date:  2022-03-01       Impact factor: 9.941
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.